Site Web du Dr Marc GIRARD

Failure in drug safety assessment: a worrying issue far beyond manufacturer’s potential conflicts of interest

Tuesday 21 December 2004 par Marc Girard

In a 20-year old communication, I asked whether post-marketing surveillance was “an art or a science”: no doubt, twenty years later, that drug monitoring is just playacting, which may evolve in tragedies. Analysis of the statin story (amongst others) comes to the sad conclusion that regulatory bodies are currently unable to guarantee the protection of public health as far as a fair assessment of drugs benefit/risk ratios.

Attached documents

21 December 2004
Document : PDF
36.8 kb

Home page | Contact | Site Map | | Statistics | visits: 1465438

Follow-up of the site's activity en  Follow-up of the site's activity Documents in English  Follow-up of the site's activity Statins   ?

Site created with SPIP 2.1.26 + AHUNTSIC

Creative Commons License

143 visitors now